NCT06427941 2026-03-18A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsBeOne MedicinesPhase 1 Recruiting140 enrolled